Commonwealth Biotechnologies Expands Presence into Japan with Opening of Tokyo Office.RICHMOND, Va. -- Commonwealth Biotechnologies, Inc. (CBI CBI abbr. cumulative book index CBI Confederation of British Industry CBI n abbr (= Confederation of British Industry) → C.E.O.E. ) (Nasdaq:CBTE) today announced its expansion into Japan through Venturepharm (Asia), with the opening of a new Tokyo office and appointment of Mikio Taniguchi as regional business development manager. The new office will focus on supplying business development and localized Translated into the spoken language of the country. See localization. customer service to the Japanese pharmaceutical and biotechnology industry. "This new office, our first in Japan, marks CBI's growth into one of the major world markets for pharmaceutical and biotechnology R&D," said Paul D'Sylva, Chief Executive Officer of CBI. "Adding this office allows us to offer our Japanese customers the added benefit of expert local client support and project management from one of the premier contract discovery research services organizations in the world, providing compound screening, medicinal medicinal /me·dic·i·nal/ (mi-dis´in-il) having healing qualities; pertaining to a medicine. me·dic·i·nal adj. Of, relating to, or having the properties of medicine. , computational and synthetic chemistry capabilities and related bioanalytical services." "We are excited to have hired an excellent business development manager for Japan," Dr. D'Sylva continued. "Mikio Taniguchi has a strong background in both business and medicinal chemistry Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacology involved with designing, synthesizing and developing pharmaceutical drugs. , having both conducted research at some of Japan's largest pharmaceutical companies and worked in the venture capital and investment banking sectors focused on the pharmaceutical and biotechnology industry. He will be responsible for providing business development and client support for CBI products and services related to drug discovery collaborations, and the products and services of our Exelgen, Mimotopes, and CBI business units." About Commonwealth Biotechnologies, Inc. Commonwealth Biotechnologies, Inc. (CBI) is a dynamic contract research organization and a partner to the global life sciences industry, offering a comprehensive, integrated range of services for the discovery and development of therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. , vaccines and diagnostic products. With the insight, innovation and project management skills that come from extensive experience, CBI offers its customers exceptional value whether they are a pharmaceutical giant or an emerging biotechnology company. CBI operates five distinct business units: (1) CBI Services, a discovery-phase contract research organization; (2) Fairfax Identity Laboratories, a DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. reference business; (3) Mimotopes Pty Ltd PTY LTD Propriety Limited (company structure in Australia) , Melbourne, Australia, a peptide peptide, organic compound composed of amino acids linked together chemically by peptide bonds. The peptide bond always involves a single covalent link between the α-carboxyl (oxygen-bearing carbon) of one amino acid and the amino nitrogen of a second amino acid. and discovery chemistry business; (4) Exelgen Ltd, Bude, UK, a medicinal and synthetic discovery chemistry business; and (5) Venturepharm Asia, Beijing, China, a contract research business unit specializing in process scale-up, formulation development, cGMP manufacturing and clinical trial management. With CBI as your partner, discovery is just the beginning. For more information, visit CBI on the web at http://www.cbi-biotech.com. Forward Looking Statements No statement made in this press release should be interpreted as an offer to purchase any security. Such an offer can only be made in accordance with the Securities Act of 1933, as amended, and applicable state securities laws. Any statements contained in this release that relate to future plans, events or performance are forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve risks and uncertainties as identified in CBI's filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially. Readers are cautioned not to place undo To restore the last editing operation that has taken place. For example, if a segment of text has been deleted or changed, performing an undo will restore the original text. Programs may have several levels of undo, including being able to reconstruct the original data for all edits reliance on these forward-looking statements, which speak only as the date hereof here·of adv. Of this. hereof Adverb Formal or law of or concerning this Adv. 1. hereof - of or concerning this; "the twigs hereof are physic" . Specifically, CBI cannot guarantee that this new business development office will produce any revenues or prospects as referenced herein. Further, CBI undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion